Coarctation of the Aorta
Conditions
Brief summary
This study is designed as a prospective, multicenter, non-randomized, single arm study to assess the safety and effectiveness of the Large Diameter Advanta™ V12 Covered Stent for stent implantation in coarctations of the aorta.
Detailed description
The performance metric for comparison is based on data from the Congenital Cardiovascular Interventional Study Consortium (CCISC) as reported by Golden and Hellenbrand \[1\]. The CCISC experience from 1989 to 2005 shows a true procedural success rate of 98.6%. The patient population will be subjects with coarctation of the aorta. A total of 70 subjects, children, adolescents and adults, will be enrolled at up to 15 study sites. Baseline clinical and angiographic assessment will determine the subject's eligibility for enrollment in the study. Subjects will continue in the study for long term annual follow-up through 3, 4, and 5 years.
Interventions
DEVICELarge Diameter Advanta™ V12 Covered Stent
Stent placement
Sponsors
Atrium Medical Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with a presence of native or recurrent coarctation of the aorta as confirmed by blood pressure gradient, 2D-echocardiography with Doppler or angiography. * Subject weighs a minimum of 30 kg. * The peak pressure gradient is ≥20 mmHg systolic blood pressure across the coarctation site. * Vessels at access site can accept a minimum size of 9 French for a 12 mm balloon and 11 French for a 14 and 16 mm balloon. * Coarctation can be successfully crossed with a guide wire, sheath and device. * Diameter of transverse arch distal to left subclavian artery is between 9.5 mm and 20 mm in diameter. * Subject is able and willing to adhere to all required follow-up visits and testing. * Subject is able and willing to adhere to the required follow-up medication regimen.
Exclusion criteria
* The physician is not able to access the coarctation with standard techniques. * Presence of other thoracic aortic arterial lesions or aneurysms requiring treatment within 30 days of the implant procedure. * Length of coarctation is greater than 45 mm in length. * Connective tissue and genetic disorders, including William, Marfan, Turner, Noonan syndrome. * The coarctation has adjacent, acute thrombus. * The coarctation was previously treated with a stent. * Proximity of the coarctation to an important side branch resulting in crossing of the side branch with the Large Diameter Advanta™ V12 Covered Stent device (e.g. jailing of the branch vessel). * Subject has a tubular graft, interposition graft, stent graft at or near the coarctation site that would be interfere with delivery, positioning, expansion or stabilization of the Large Diameter Advanta™ V12 Covered Stent * Subject has contrast agent hypersensitivity that cannot be adequately premedicated, has a hypersensitivity to stainless steel, expanded polytetrafluoroethylene (ePTFE) or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications. * Bloodstream infection * Subject is pregnant or breastfeeding. * Subject has a co-morbid illness that may result in a life expectancy of less than 1 year. * The investigator deems the subject to be an inappropriate candidate for the study. * Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now approved product are not excluded by this criterion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Efficacy | 12 month | The mean difference between Diastolic Velocity (DV)/Systolic Velocity(SV) pre and post procedure (i.e. pre procedure DV/SV - post procedure DV/SV) minus the difference between 12 month and post procedure (i.e. 12 month DV/SV - post procedure DV/SV). |
| Primary Safety | 30 days of procedure | 30 day morbidity rate of Major Adverse Events (MAE)and Major Adverse Vascular Events (MAVE) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Safety | procedural (time zero) | Device success, defined as the successful delivery and deployment of the study stent and intact retrieval of the delivery system. |
Countries
Australia, Brazil, Canada, Germany, Israel, Italy, United Kingdom
Outcome results
None listed